A Model-Based Estimation of RSV-Attributable Incidence of Hospitalizations and Deaths in Italy Between 2015 and 2019
- PMID: 39289329
- PMCID: PMC11499556
- DOI: 10.1007/s40121-024-01041-x
A Model-Based Estimation of RSV-Attributable Incidence of Hospitalizations and Deaths in Italy Between 2015 and 2019
Abstract
Introduction: Respiratory syncytial virus (RSV) incidence is known to be underestimated in adults due to its infrequent diagnostic testing and lower sensitivity of single nasal/nasopharyngeal swab PCR testing outside of the early childhood period. RSV can trigger acute cardiac events as well as cause respiratory disease. Consequently, we used a model-based study to estimate RSV-attributable hospitalization and mortality incidence among adults in Italy between 2015 and 2019.
Methods: Through a database predisposed by CREA Sanità, by extracting monthly data from the Italian hospitalization collection data of the Ministry of Health and the Italian National Institute of Statistics (ISTAT) data (mortality), we estimated yearly RSV-attributable incidence of events for different cardiorespiratory outcomes. We used a quasi-Poisson regression model, which accounted for periodic and aperiodic time trends and viral activity proxies.
Results: The yearly RSV-attributable cardiorespiratory hospitalization incidence increased with age and was highest among adults aged ≥ 75 years (1064-1527 cases per 100,000 person-years). Similarly, the RSV-attributable cardiorespiratory mortality rate was highest among persons aged ≥ 75 years (59-85 deaths per 100,000 person-years). Incidence rates for RSV-attributable hospitalizations and RSV-attributable mortality were on average 2-3 times higher for cardiorespiratory than respiratory disease alone. Incidence rate based on RSV-specific ICD codes only were 405-1729 times lower than modeled estimates accounting for untested events.
Conclusion: RSV causes a substantial disease burden among adults in Italy and contributes to both respiratory and cardiovascular conditions. Our results emphasize the need for effective RSV prevention strategies, particularly among older adults.
Keywords: Disease burden; Hospitalization; Incidence; Mortality; Respiratory syncytial virus.
© 2024. Pfizer Inc.
Conflict of interest statement
Caihua Liang, Raffaella Iantomasi, Giuseppe Pietro Innocenti, Bradford D. Gessner, and Elizabeth Begier are employees of Pfizer and may own Pfizer stock. Estelle Méroc, Chukwuemeka Onwuchekwa, Solomon Molalign, Thao Mai Phuong Tran, Somsuvro Basu, Robin Bruyndonckx and Aleksandra Polkowska-Kramek are employees of P95, which received funding from Pfizer to conduct this study and for manuscript development.
Similar articles
-
Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Australia Between 2010 and 2019.Influenza Other Respir Viruses. 2025 Apr;19(4):e70092. doi: 10.1111/irv.70092. Influenza Other Respir Viruses. 2025. PMID: 40254721 Free PMC article.
-
Estimated Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain, 2016-2019.Infect Dis Ther. 2024 Mar;13(3):463-480. doi: 10.1007/s40121-024-00920-7. Epub 2024 Feb 6. Infect Dis Ther. 2024. PMID: 38319540 Free PMC article.
-
Estimated Incidence of Hospitalizations and Deaths Attributable to Respiratory Syncytial Virus Infections Among Adults in Germany Between 2015 and 2019.Infect Dis Ther. 2024 Apr;13(4):845-860. doi: 10.1007/s40121-024-00951-0. Epub 2024 Mar 23. Infect Dis Ther. 2024. PMID: 38520629 Free PMC article.
-
Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis.J Infect Dis. 2023 Jul 14;228(2):173-184. doi: 10.1093/infdis/jiad012. J Infect Dis. 2023. PMID: 36661222 Free PMC article.
-
Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.Lancet Infect Dis. 2024 Sep;24(9):974-1002. doi: 10.1016/S1473-3099(24)00176-2. Epub 2024 Apr 15. Lancet Infect Dis. 2024. PMID: 38636536 Free PMC article.
Cited by
-
Estimating the respiratory syncytial virus-associated hospitalisation burden in older adults in European countries: a systematic analysis.BMC Med. 2025 Aug 4;23(1):453. doi: 10.1186/s12916-025-04249-x. BMC Med. 2025. PMID: 40754579 Free PMC article.
-
Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Australia Between 2010 and 2019.Influenza Other Respir Viruses. 2025 Apr;19(4):e70092. doi: 10.1111/irv.70092. Influenza Other Respir Viruses. 2025. PMID: 40254721 Free PMC article.
-
Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Norway between 2010 and 2019: A Time-Series Modelling Study.J Epidemiol Glob Health. 2025 Aug 14;15(1):107. doi: 10.1007/s44197-025-00448-0. J Epidemiol Glob Health. 2025. PMID: 40810757 Free PMC article.
References
-
- Ivey KS, Edwards KM, Talbot HK. Respiratory syncytial virus and associations with cardiovascular disease in adults. J Am Coll Cardiol. 2018;71(14):1574–83. - PubMed
-
- Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–59. - PubMed
-
- Tseng HF, Sy LS, Ackerson B, Solano Z, Slezak J, Luo Y, et al. Severe morbidity and short- and mid- to long-term mortality in older adults hospitalized with respiratory syncytial virus infection. J Infect Dis. 2020;222(8):1298–310. - PubMed
LinkOut - more resources
Full Text Sources